Latest Conference Content

Experts reevaluate coverage policies and the financial impact of antiobesity medications based on updated clinical data and key utilization trends.

The phase 2 PICCOLO trial demonstrated that mirvetuximab soravtansine (Elahere; AbbVie) is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.

Financial advocacy in health care should advocate for system change and community work to give people better access to health and well-being before they get a life-changing cancer diagnosis, said Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.

Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.

Financial toxicity and patient and staff wellness were well explored at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference, serving as the focal point of multiple posters and presentations.

One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.

Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, highlighting the urgent need for providers to address the escalating impacts of climate change on lung health.

During CHEST 2024, Maxine Dexter, MD, Kaiser Permanente, discussed her belief in the vital role of physicians in public health advocacy, drawing from her legislative work on issues as a former Oregon State Representative.

Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital, discusses therapies and management guidelines for patients with interstitial lung disease (ILD).

An integrated, rule-based informatics system demonstrated its capacity to leverage electronic health records to streamline the prior authorization process and promote the use of biosimilars.

Io Hui, PhD, researcher at The University of Edinburgh, discusses challenges to implementing artificial intelligence in respiratory care.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation.

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in patients with heart failure with reduced ejection fraction (HFrEF), while also addressing prescription barriers for providers.

The 41st Association of Cancer Care Centers (ACCC) National Oncology Conference began with a diverse range of poster exhibits, highlighting important initiatives in patient wellness.

CHEST 2024 late-breaking data showcased the potential of AI-based systems in diagnosing and managing pulmonary embolism.

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of chronic obstructive pulmonary disease (COPD), with better adherence and outcomes among those using single-inhaler triple therapy.

Research from the Heart Failure Society of America Annual Scientific Meeting evaluated remote physiological monitoring for treating systolic heart failure (HF), as well as the impact of a heart transplant allocation system on urban and rural communities.

Chronic obstructive pulmonary disease (COPD) presents a significant challenge for both patients and health care providers and discussions of effective management strategies took center stage at CHEST 2024 in Boston.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, discusses key agenda highlights that will be presented at the 2024 AMCP Nexus conference.

A poster presented at the CHEST 2024 annual meeting shows that inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD).

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive pulmonary disease (COPD).

New data presented at CHEST 2024 in Boston revealed a significant link between obstructive sleep apnea and mental health disorders in middle-aged and older adults.

At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to address issues like air pollution and health equity in respiratory care.

The Heart Failure Society of America (HFSA) annual meeting 2024 was scheduled to showcase groundbreaking research on the impact of COVID-19 on patients with myocarditis and heart failure.

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.

Krunal Patel, MD, Temple University Hospital, highlights CHEST 2024 data revealing why timing matters with acute pulmonary embolism (PE) intervention.